(0)
Regulatory News:
CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, informs its shareholders that the annual general meeting (AGM) of May 12, 2021 was able to deliberate, quorum having been reached.
Given the ongoing restrictions associated with the COVID-19 context, CARMAT's AGM was held behind closed doors and streamed online. This AGM approved all the resolutions tabled, with the exception of the 26
th resolution, which was rejected on the recommendation of the Board of Directors.